Drug Designing: Open Access
Open Access

Formulation development for enhanced anti-inflammatory effect of eugenol using transdermal solid lipid nanoparticle

9^th Annual Congress on Drug Design & Drug Formulation

October 19-20, 2017 Seoul, South Korea

Abdulmohsen H Al Rohaimi and Gulam Mustafa

Shaqra University, KSA

Posters & Accepted Abstracts: Drug Des

Abstract :

The clove essential oil has shown potential antioxidant, anti-inflammatory, anti-bacterial and anti-fungal activity since ancient time. Eugenol is the main compound which contributes to such therapeutic benefits. Besides their excellent therapeutic potential, low bioavailability was considered one of the major constraints for its clinical utility. Various formulations approaches have been used for the improvement of bioavailability of eugenol, nano-delivery approach being one of the most notable approaches among them. Therefore, present study was designed to convert eugenol into solid lipid nanoparticle (NanoEug). Eugenol-incorporated lipid nanoparticles were prepared by hot aqueous titration method followed by high-pressure homogenization using glyceryl monostearate as a solid lipid and soya phosphatidylcholine/polysorbate 80 as a co-surfactant and surfactant respectively. The formulation were pre-screen by different physical stress tests, followed by in vitro release study, surface charge (zeta potential), viscosity, transmittance, globule size distribution and finally by ex vivo studies. The shape of the NanoEug was determined using transmission electron microscopy (TEM) which showed good correlation with dynamic light scattering study. The NanoEug was converted into gel using Cabopol 934. The composition of final optimized NanoEug was eugenol (0.25% w/w), Carbopol 934 (0.702% w/w), Polysorbate 80 (0.525%w/w) as surfactant, soya phosphatidylcholine (0.28% w/w) as a co-surfactant and distilled water (q.s) as hydration phase. The steady state flux (Jss), permeability coefficient (Kp) and enhancement ratio (Er) of NanoEug gel was determined and compared with simple EugGel. The formulations showed biphasic drug release pattern with a burst release within 67.3�?±5.24 minutes followed by a sustained release for 81.5�?±9.4 hours. The histo-pathological study showed reversible disruption in the integrity of skin proving permeation potential of the optimized formulations. Finally, it was concluded that NanoCur can be a promising tool for the management of topical inflammation.